Joeffre Braga, Emily J Y Kuik, Mariel Lepra, Pablo M Rusjan, Stephen J Kish, Erica L Vieira, Zahra Nasser, Natasha Verhoeff, Neil Vasdev, Thomas Chao, Michael Bagby, Isabelle Boileau, Stefan Kloiber, M Ishrat Husain, Nathan Kolla, Yuko Koshimori, Khunsa Faiz, Wei Wang, Jeffrey H Meyer
{"title":"Astrogliosis Marker [<sup>11</sup>C]SL25.1188 After COVID-19 With Ongoing Depressive and Cognitive Symptoms.","authors":"Joeffre Braga, Emily J Y Kuik, Mariel Lepra, Pablo M Rusjan, Stephen J Kish, Erica L Vieira, Zahra Nasser, Natasha Verhoeff, Neil Vasdev, Thomas Chao, Michael Bagby, Isabelle Boileau, Stefan Kloiber, M Ishrat Husain, Nathan Kolla, Yuko Koshimori, Khunsa Faiz, Wei Wang, Jeffrey H Meyer","doi":"10.1016/j.biopsych.2024.09.027","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>After acute COVID-19, 5% of people experience persistent depressive symptoms and reduced cognitive function (COVID-DC). Theoretical models propose that astrogliosis is important in long COVID, but measures primarily indicative of astrogliosis have not been studied in the brain of long COVID or COVID-DC. The objective of the current study was to measure [<sup>11</sup>C]SL25.1188 total distribution volume ([<sup>11</sup>C]SL25.1188 V<sub>T</sub>), an index of monoamine oxidase B density and a marker of astrogliosis, with positron emission tomography in participants with COVID-DC and compare with healthy control participants.</p><p><strong>Methods: </strong>In 21 COVID-DC cases and 21 healthy control participants, [<sup>11</sup>C]SL25.1188 V<sub>T</sub> was measured in the prefrontal cortex, anterior cingulate cortex, hippocampus, dorsal putamen, and ventral striatum. Depressive symptoms were measured with the Beck Depression Inventory-II, and cognitive symptoms were measured with neuropsychological tests.</p><p><strong>Results: </strong>[<sup>11</sup>C]SL25.1188 V<sub>T</sub> was higher in participants with COVID-DC in the prefrontal cortex, anterior cingulate cortex, hippocampus, dorsal putamen, and ventral striatum than in healthy control participants. Depressive symptom severity negatively correlated with [<sup>11</sup>C]SL25.1188 V<sub>T</sub> across prioritized brain regions. More recent acute COVID-19 positively correlated with [<sup>11</sup>C]SL25.1188 V<sub>T</sub>, reflecting higher values since predominance of the Omicron variant. Exploratory analyses found greater [<sup>11</sup>C]SL25.1188 V<sub>T</sub> in the hippocampus, dorsal putamen, and ventral striatum of COVID-DC participants than control participants with a major depressive episode with no history of COVID-19, and there was no relationship to cognitive testing in prioritized regions.</p><p><strong>Conclusions: </strong>Results strongly support the presence of monoamine oxidase B-labeled astrogliosis in COVID-DC throughout the regions assessed, although the association of greater astrogliosis with fewer symptoms raises the possibility of a protective role. The magnitude of astrogliosis in COVID-DC is greater since the emergence of the Omicron variant.</p>","PeriodicalId":8918,"journal":{"name":"Biological Psychiatry","volume":" ","pages":""},"PeriodicalIF":9.6000,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biological Psychiatry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.biopsych.2024.09.027","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
引用次数: 0
Abstract
Background: After acute COVID-19, 5% of people experience persistent depressive symptoms and reduced cognitive function (COVID-DC). Theoretical models propose that astrogliosis is important in long COVID, but measures primarily indicative of astrogliosis have not been studied in the brain of long COVID or COVID-DC. The objective of the current study was to measure [11C]SL25.1188 total distribution volume ([11C]SL25.1188 VT), an index of monoamine oxidase B density and a marker of astrogliosis, with positron emission tomography in participants with COVID-DC and compare with healthy control participants.
Methods: In 21 COVID-DC cases and 21 healthy control participants, [11C]SL25.1188 VT was measured in the prefrontal cortex, anterior cingulate cortex, hippocampus, dorsal putamen, and ventral striatum. Depressive symptoms were measured with the Beck Depression Inventory-II, and cognitive symptoms were measured with neuropsychological tests.
Results: [11C]SL25.1188 VT was higher in participants with COVID-DC in the prefrontal cortex, anterior cingulate cortex, hippocampus, dorsal putamen, and ventral striatum than in healthy control participants. Depressive symptom severity negatively correlated with [11C]SL25.1188 VT across prioritized brain regions. More recent acute COVID-19 positively correlated with [11C]SL25.1188 VT, reflecting higher values since predominance of the Omicron variant. Exploratory analyses found greater [11C]SL25.1188 VT in the hippocampus, dorsal putamen, and ventral striatum of COVID-DC participants than control participants with a major depressive episode with no history of COVID-19, and there was no relationship to cognitive testing in prioritized regions.
Conclusions: Results strongly support the presence of monoamine oxidase B-labeled astrogliosis in COVID-DC throughout the regions assessed, although the association of greater astrogliosis with fewer symptoms raises the possibility of a protective role. The magnitude of astrogliosis in COVID-DC is greater since the emergence of the Omicron variant.
期刊介绍:
Biological Psychiatry is an official journal of the Society of Biological Psychiatry and was established in 1969. It is the first journal in the Biological Psychiatry family, which also includes Biological Psychiatry: Cognitive Neuroscience and Neuroimaging and Biological Psychiatry: Global Open Science. The Society's main goal is to promote excellence in scientific research and education in the fields related to the nature, causes, mechanisms, and treatments of disorders pertaining to thought, emotion, and behavior. To fulfill this mission, Biological Psychiatry publishes peer-reviewed, rapid-publication articles that present new findings from original basic, translational, and clinical mechanistic research, ultimately advancing our understanding of psychiatric disorders and their treatment. The journal also encourages the submission of reviews and commentaries on current research and topics of interest.